We used CDK4/hTERT-immortalized normal human bronchial epithelial cells (HBEC) from several individuals to study lung cancer pathogenesis by introducing combinations of common lung cancer oncogenic changes (p53, KRAS, and MYC) and followed the stepwise transformation of HBECs to full malignancy. This model showed that: (i) the combination of five genetic alterations (CDK4, hTERT, sh-p53, KRAS
Introduction
Human lung cancer develops as a multistep process, usually after prolonged smoke-related tobacco exposure resulting in specific proto-oncogene and tumor suppressor gene alterations in lung epithelial cells (1) . Genome-wide analyses have identified multiple genetic and epigenetic alterations in lung tumors (2) (3) (4) (5) . To translate these findings to the clinic, however, it is essential to identify the best targets for early detection and therapeutic intervention by determining which alterations represent "driver" and which represent "passenger" changes.
Functional tests are a critical step in determining "driver" status and are most commonly conducted by genetically or pharmacologically "correcting" the defect in a lung cancer line and monitoring its effect. Another approach is to introduce putative oncogenic changes into normal lung epithelial cells and ascertain their contribution to malignancy. To undertake the latter, we previously developed an in vitro model of immortalized human bronchial epithelial cells (HBEC) establishing cell lines from more than 30 different individuals (6) . HBECs were immortalized by overexpressing Cdk4 and human telomerase reverse transcriptase (hTERT) to emulate 2 of the earliest events and almost universal events in lung cancer pathogenesis: abrogation of the p16/Rb cell-cycle checkpoint pathway and bypass of replicative senescence. Importantly, this was the first report of immortalizing lung epithelial cells in the absence of viral oncoproteins, as used previously by other groups (7, 8) . Viral oncoproteins such as SV40 early region (containing large T and small t antigens) are known to cause malignant transformation through inactivation of retinoblastoma (Rb) and/ or p53, as well as inhibit the tumor suppressor gene PP2A phosphatase (9, 10) . They also have other less characterized interactions with cellular processes, thereby contributing to cancer pathogenesis in unknown ways. Thus, the critical genetic manipulations that lead to malignant transformation of epithelial cells immortalized with viral oncoproteins are not completely "defined." Moreover, they are likely more oncogenically progressed than nonviral models as shown in mammary epithelial cell systems where full transformation with SV40 early region required 3 manipulations (hTERT, SV40 early region, and RAS; ref. 8 ) as compared with 6 manipulations (hTERT, dominant-negative p53, CDK4, c-MYC, and cyclin D1) in the absence of SV40 early region (11) .
While HBECs used in our study are immortalized, a phenotype they share with cancer cells, they do not display other cancer cell phenotypes such as disruption of the p53 pathway, extensive copy number changes, lack of contactinhibition, anchorage-independent growth, and the ability to form tumors in immunodeficient mice (6, 12) . Furthermore, we have shown that immortalized HBECs retain the ability to differentiate into structures found in the normal bronchial epithelium (13, 14) . These features make HBECs a physiologically appropriate in vitro model for studying the transformation process of bronchial epithelial cells to lung cancer.
Transformation of lung epithelial cells to full malignancy using defined genetic manipulations has only been described in 2 studies (8, 15) . One study using viral oncoproteins-transformed tracheobronchial and small airway epithelial cells with hTERT, SV40 early region, and oncogenic HRAS or KRAS (8) . The second study showed fully transformed human small airway epithelial cells (HSAEC) occurred with CDK4, hTERT, mutant p53, mutant KRAS, and either c-MYC, PIK3CA, cyclin D1, or LKB1 manipulations (15) . In our bronchial epithelial cell model, we have previously shown the combination of CDK4, hTERT, and p53 knockdown with mutant EGFR, or moderate levels of mutant KRAS V12 progressed cells partially but not completely to malignancy, as evidenced by the failure to form tumors in immunodeficient mice (12) . As lung cancer develops in both the central bronchus and peripheral small airways, development of an in vitro model of malignant transformation in bronchial epithelial cells is essential.
In the present study, we aimed to confirm the genetic tractability of HBECs and fully transform cells to malignancy using oncogenic manipulations commonly found in lung tumors. Loss of p53 function and oncogenic KRAS are 2 well-known genetic alterations in lung cancer occurring in approximately 50% and 30% of non-small cell lung carcinoma (NSCLC), respectively (16, 17) . Aberrant expression of c-MYC, through amplification or overexpression, is found in approximately 20% of NSCLCs (1) . While it is known that protein levels of oncogenic RAS can influence its oncogenic ability (18) , expression of oncogenic KRAS V12 can also lead to premature senescence of normal human epithelial cells (19) . The prevalence of KRAS alterations in NSCLC indicates however that malignant transformation requires the cell to adapt to this oncogenic stress, perhaps assisted through preceding oncogenic transformations (20) . Here, we present one of the first reports of full malignant transformation of lung epithelial cells with defined genetic manipulations. Furthermore, we characterize the effect of oncogenic stress and environmental effects such as growth factors upon tumorigenic transformation in HBECs, illustrate divergent clonal heterogeneity, and determine the capability of this in vitro model for developing and testing lung cancer therapeutics.
Materials and Methods

Cells and culture conditions
HBEC3 (HBEC3KT), HBEC4 (HBEC4KT), and HBEC17 (HBEC17KT) immortalized normal HBEC lines were established by introducing mouse Cdk4 and hTERT into normal HBECs (6) . HBECs were cultured with keratinocyte serum-free medium (KSFM; Life Technologies Inc.) media containing 50 mg/mL of bovine pituitary extract (BPE; Life Technologies Inc.) and 5 ng/mL of EGF (Life Technologies Inc.). Partially transformed HBECs (soft agar clones) were also cultured with RPMI-1640 (Life Technologies Inc.) media supplemented with 10% FBS (R10). Lung cancer cell lines were established by our laboratory and maintained in RPMI-1640 (Life Technologies Inc.) with 5% FBS (21, 22) . All cell lines were DNA-fingerprinted (PowerPlex 1.2 Kit; Promega) and Mycoplasma-free (e-Myco Kit; Boca Scientific).
Viral vector construction and viral transduction
Stable p53 knockdown and moderate expression of KRAS V12 was achieved as described previously (12) . Expression of high KRAS V12 levels used a lentiviral vector, pLenti6-KRAS V12 , as described previously (23) . Lentiviral vectors expressing KRAS WT , KRAS
C12
, and KRAS D12 were constructed from pLenti6-KRAS V12 as described previously (24) . A c-MYC-expressing retroviral vector (designated pMSCV-MYC) was constructed by ligating a BamHI/ SalI-digested c-MYC insert from pCTV3K (ref. 25 ; a gift from Dr. J. Michael Ruppert, University of Alabama, Tuscaloosa, AL) into BglII/XhoI-digested pMSCV-hyg (Clontech). Lentivirus and retrovirus-containing medium were produced as described previously (12) . Transduced cells were selected with zeocin (12.5 mg/mL), blasticidin (2 mg/mL), or hygromycin (20 mg/mL) for 7 to 14 days. The presence of mutant KRAS V12 in stable cell lines was confirmed using a reverse transcription PCR (RT-PCR)/RFLP assay, as described previously (12) .
Immunoblotting and southern blotting
Preparation of total cell lysates and Western blotting were carried out as described previously (26) . Primary antibodies are listed in Supplementary Table S1 and were detected with horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse secondary antibodies (1:2,000 dilution; Thermo Fisher Scientific). Actin or HSP90 protein levels were used as loading controls. Southern blotting for HBEC clones derived from large soft agar colonies was carried out as described previously (27) using Phototope-Star Detection Kit (New England Biolabs). DNA was probed with the blasticidin-resistance gene amplified from pLenti6-KRAS V12 vector using 5 0 -ATGGCCAAGCCTTTGTCT-CAAG-3 0 and 5 0 -TTAGCCCTCCCACACATAACC-3 0 primers.
Biochemical and in vitro transformation assays Senescent cells were stained with Senescence b-Galactosidase Staining Kit (Cell Signaling) and blue-stained senescent cells were counted under a microscope (Â20 total magnification). Percentage of positively stained cells was averaged across 6 fields. Cell-cycle analysis was conducted on subconfluent populations of cells harvested 48 hours after seeding, unless otherwise stated, and cell-cycle analysis was conducted as described previously (28) . Cell proliferation assays were conducted by seeding 5,000 cells in 6-well plates and counting cells every 4 days. Cells were expanded when subconfluent, as necessary. Anchorage-dependent colony formation assays were conducted as previously described (12) ; 200 to 600 viable cells were seeded in triplicate in 100-mm plates and cultured for 2 weeks before staining colonies with methylene blue. Acute KRAS V12 toxicity assays were conducted by transducing cells with KRAS V12 or LacZ lentivirus and selecting for 3 days with blasticidin before seeding anchorage-dependent colony formation assays. Anchorage-independent (soft agar) growth assays were conducted as previously described (12) seeding 1,000 viable cells in 12-well plates. MTS assays to measure drug response to standard platinum-based doublets [paclitaxel-carboplatin (2/3 wt/wt), gemcitabine-cisplatin (25/2 wt/wt), and pemetrexed-cisplatin (20/3 wt/wt)] were conducted as previously described (29) . Cells were treated for 96 hours with 4-fold dilutions from a maximum dose of 1,000/3,501 nmol/L (paclitaxel/carboplatin), 1,000/298 mmol/L (pemetrexedcisplatin), or 2,000/140 nmol/L (gemcitabine/cisplatin). Each experiment was carried out in quadruplicate with 8 replicates per experiment. Fitting of data to dose-response inhibition curves, calculation of ED 50 values, and comparisons based on one-way ANOVA with Dunnett posttest were conducted using GraphPad Prism version 5.00 for Windows (GraphPad Software).
In vivo tumorigenicity assays and histologic analysis
In vivo tumorigenicity was evaluated by injection of cells in female 5-to 6-week-old nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Each mouse was given a subcutaneous injection on its flank of 3 to 5 Â 10 6 viable cells in 0. 
Results
Oncogenic transformation of HBECs correlates with level of exogenous KRAS
V12 expression NSCLC cell lines harboring a mutation in KRAS express wide-ranging endogenous levels of the protein (Fig. 1A) . Thus, to create HBECs that express comparable levels of oncogenic KRAS protein, we used 2 different expression vectors: a retroviral vector, which resulted in modest levels of expression, and a lentiviral vector that resulted in high levels of expression (Fig. 1A) . Compared with HBEC3 expressing moderate levels (retroviral-mediated) of KRAS V12 protein, HBEC3 expressing high levels of KRAS V12 (lentiviralmediated) exhibited a significant increase in soft agar colonies in the background of both wild-type p53 (HBEC3) and p53 knockdown (HBEC3 p53 ; Fig. 1B ). To confirm the contribution of the level of KRAS V12 expression toward HBEC transformation, we examined 7 clonal populations of HBEC3 p53,KRAS (sh-p53 and lentiviral-delivered KRAS V12 ; Fig. 1C ). Clones with high levels of KRAS expression had increased anchorage-dependent (liquid) colony-forming ability ( Fig. 1D and Supplementary Fig. S1A ).
High levels of mutant KRAS
V12 induce senescence in HBECs, in a p53-dependent manner Lentiviral-mediated introduction of high levels of KRAS V12 caused a large subset of HBEC3 cells to display significant morphologic changes, including flattened, enlarged shape, and a vacuole-rich cytoplasm, suggestive of oncogene-induced senescence. This effect was not observed following exogenous expression of moderate levels of KRAS V12 ( Supplementary Fig. S1B ). Senescence-associated b-galactosidase (SA-b-gal) staining confirmed the morphologic changes corresponded with senescence ( Supplementary  Fig. S1C ). Significantly less RAS-induced senescence was observed in HBEC3 with stable p53 knockdown (HBEC3 p53 ) compared with HBEC3 with wild-type p53 ( Fig. 1E and Supplementary Fig. S1C ). An acute, senescence-associated p53-mediated KRAS V12 toxicity was shown in anchorage-dependent colony formation assays seeded 4 days after transduction with KRAS V12 lentivirus. Significant toxicity was observed in HBECs with wild-type p53 (HBEC3 and another HBEC line, HBEC4) following transduction with KRAS V12 lentivirus compared with control LacZ lentivirus but not in HBECs with p53 knockdown ( Fig. 1F and Supplementary Fig. S1D and S1E), suggesting induced senescence was p53-dependent. p53-mediated mitigation of oncogenic KRAS stress was also observed with other codon 12 KRAS mutants (KRAS C12 and D12 ; Supplementary Fig. S1F and S1G), whereas overexpression of wild-type KRAS in HBEC3 did not induce a senescence phenotype ( Supplementary Fig. S1G ). Immunoblotting for cleaved caspase-3 confirmed KRAS V12 -induced toxicity was not apoptosis-associated (Fig. 1G) , whereas cell-cycle analysis found no increased accumulation of cells in G 1 -phase in HBEC3 p53 cells infected with KRAS V12 as compared with the control vector ( Supplementary Fig. S1H ). 
G F E + -
These results show that oncogenic KRAS mediates a potent cellular stress response in CDK4/hTERT-immortalized HBECs, whereby the cells resist oncogenic transformation by engaging cellular senescence. Loss of p53 function however impedes this cellular senescence response, indicating that in these cells, p53 signaling is a primary mediator of RAS-induced senescence. Furthermore, as high levels of oncogenic KRAS expression are required for malignant transformation, it shows that loss of p53 function is a critical co-oncogenic step in the malignant transformation of the large majority of HBECs.
The combination of p53 knockdown and KRAS V12 in HBECs significantly increases in vitro transformation, which is further augmented with c-MYC overexpression
The single introduction of p53 knockdown, mutant KRAS V12 or c-MYC overexpression resulted in quantitatively modest but significant increases in soft agar colony number ( Fig. 2A-C (Table 1 and Fig. 3 ). Squamous and adenocarcinoma differentiation was confirmed by p63 and mucicarmine/Alcian Blue-PAS positivity, respectively, and pathology was verified by an independent lung cancer pathology expert. Adenocarcinomas were found to be strongly cytokeratin 5-positive, whereas negative for Napsin A and the squamous cell marker, cytokeratin 7 ( Supplementary Fig. S2A ). In all cases, adenocarcinoma differentiation was TITF1(NKX2-1)-negative (data not shown), most likely a reflection of the HBECs being derived from central airway cells. The fact that glandular cells are negative for both TITF-1 and Napsin A is not unexpected as the vast majority of adenocarcinomas (and glandular component in adenosquamous carcinomas) in whole tissue sections are either positive for both or negative for both. The development of different tumor histologies from the same HBEC-manipulated population suggests either clonal selection or the cells respond to differentiation signals in vivo.
Exploration of interindividual differences in HBEC transformation
To compare interindividual differences in malignant transformation using the same combination of oncogenic changes, we tested HBEC17, derived from a different individual than HBEC3. We observed a similar transformed phenotype in vitro ( Supplementary Fig. S2B ) however, in contrast to HBEC3, HBEC17 was significantly more resistant to full in vivo transformation ( Table 1) . The difference in tumor formation rate between HBECs derived from different donors suggests the existence of interindividual differences in susceptibility to specific oncogene-induced malignant transformation. In addition to viral oncoproteins, many previous studies that succeeded in transforming normal cells to malignancy also used serum-containing medium instead of defined serum-free medium (31) (32) (33) . We have previously shown that CDK4/hTERT-immortalized HBECs with no additional oncogenic manipulations require EGF, a supplement present in KSFM medium, for cell growth, but oncogenic transformation with p53 knockdown and KRAS V12 allows the cells to become EGF-independent (12) . In the present study, we show while HBEC3 cannot tolerate growth in RPMI-1640 supplemented with serum (FBS), media commonly used for growth of cancer cell lines, HBEC3 p53,KRAS , is adaptable and will proliferate (Supplementary Fig. S3A ). Serum-supplemented media has been shown to induce differentiation of epithelial cells in culture (34) . Therefore, to further delineate the differences between HBEC3 compared with HBEC3
p53,KRAS and HBEC3 p53,KRAS,MYC following growth in serum-supplemented media, cells grown in either serum-free KSFM or serum-supplemented (5% FBS) KSFM for 96 hours were then analyzed for expression of a panel of lung differentiation and cancer stem cell (CSC) markers by quantitative RT-PCR (qRT-PCR). All 3 cell lines expressed high levels of basal markers (KRT5 and KRT14), low levels of central airway epithelial cell markers (MUC1 and TUBB4), with undetectable expression of peripheral airway markers (CC10 and SPC) in line with cells derived from bronchial epithelial cells ( Supplementary  Fig. S3B ). Aldehyde dehydrogenase (ALDH) activity has been shown to be a marker of CSCs in the lung (28) . We therefore measured the expression of 2 ALDH isozymes, ALDH1A1 and ALDH1A3, to find all the 3 cell lines that expressed ALDH1A3 with much lower expression of ALDH1A1. Growth in serum-containing medium resulted in all 3 cell lines exhibiting significant decrease in the expression of basal markers (KRT5 and KRT14), most notably in HBEC3 (Supplementary Fig. S3C ). Expression of central airway markers, particularly MUC1, increased more than 10-fold in HBEC3 when cells were grown in serum-supplemented medium, whereas HBEC3 Supplementary Fig. S3D ), whereas this was largely absent in HBEC3 p53,KRAS cells and completely absent in HBEC3 p53,KRAS,MYC . Furthermore, HBEC3
p53,KRAS,MYC and to a lesser extent HBEC3 p53,KRAS developed an elongated mesenchymal morphology after short-term growth in serum (Supplementary Fig. S3D ). Together, these data show that serum-supplemented medium induces differentiation in parental HBEC3 cells; however, oncogenic transformation enables the cells to resist serum-induced differentiation and instead undergo epithelial-to-mesenchymal transition (EMT).
We reasoned that partially transformed HBECs that have adapted to growth in serum-supplemented RPMI-1640 may differ in tumorigenicity compared with cells grown in KSFM. Therefore, to compare the effect of genetic and environmental manipulations, HBEC3 p53,KRAS and HBEC3 p53,KRAS,MYC were grown in either defined KSFM (serum-free) medium or RPMI medium supplemented with 10% FBS (R10) for at least 3 weeks, then injected subcutaneously in NOD/SCID mice (Table 1) . Growth in serumcontaining medium markedly increased in vivo tumorigenicity, decreased tumor latency, and tumors in general were more undifferentiated (e.g., large cell and giant cell carcinomas), particularly in HBEC3 p53,KRAS,MYC (Table 1  and Fig. 3 ). This effect is similar to what is observed in patients where poorly differentiated lung tumors are generally associated with aggressive tumor growth. To determine if the rate of apoptosis differed between poor and well-differentiated xenograft tumors, FFPE sections were analyzed with a TUNEL assay. There was no significant difference in the rate of apoptosis in relation to differentiation although a moderate well-differentiated SCC and giant cell carcinoma showed the greatest amount of TUNEL staining (Supplementary Fig. S3E ). Overall, the increase in tumorigenicity of oncogenically progressed HBECs after growth in serum shows the influential role of exogenous serum-derived factors in the malignant progression of lung cancer. In HBEC3 p53,KRAS cells, overexpression of c-MYC (in defined KSFM medium) or growth in serum-containing RPMI-1640 medium led to increased oncogenic transformation, as shown by soft agar colony formation and in vivo tumor growth. Both of these manipulations also led to HBEC3 p53,KRAS cells exhibiting a more mesenchymal-like morphology (Fig. 4A) . Loss of E-cadherin (epithelial marker) and gain of vimentin and N-cadherin (mesenchymal markers) confirmed an EMT (Fig. 4B) Fig. 4C ), with upregulation of EMT-promoting genes following growth in serum-containing media.
Isogenic soft agar clones of oncogenically manipulated HBEC3 represent independent genetic events with distinct in vivo growth, tumor histology, and differentiation
The genetic combinations of shp53þKRAS V12 or shp53þKRAS V12 þc-MYC in HBEC3 led to the formation of a small subset (0.5%-1.5% of all soft agar colonies) of very large, macroscopically visible (>1 mm) colonies when grown in soft agar, which was not observed with any single manipulation (shp53, KRAS V12 , or c-MYC) nor dual combination of sh-p53 or KRAS V12 with c-MYC (Fig. 2C) . Seven HBEC3 p53,KRAS clones and 4 HBEC3 p53,KRAS,MYC clones were isolated from these large colonies and repeat soft agar assays confirmed that the large colony phenotype was maintained (Fig. 5A) . Southern blotting showed the clones represent independent transformation events as indicated by discrete digestion patterns ( Supplementary Fig. S4A ) and immunoblotting confirmed HBEC3 p53,KRAS and HBEC3
p53,KRAS,MYC
clones maintained their exogenously introduced oncogenic manipulations (Figs. 1C and 5B, respectively; summarized in Supplementary Table S2 ). While immortalized but nontransformed HBECs preferentially grow in serumfree conditions, they require serum for anchorage-independent growth (Supplementary Fig. S4B ). Remarkably, following isolation from soft agar (in KSFMþ20% FBS) 9 of 11 clones were serum growth factor-dependent as they clustering. F, Kaplan-Meier log-rank analysis of overall survival in patients with lung cancer predicted to have good (black) or poor (red) outcome using the 171 probe signature HBEC3 p53,KRAS soft agar signature. A supervised principal component analysis was used to train the model in one dataset (Consortium) and test in a second dataset (SPORE; top) then the datasets were reversed to test for model robustness (bottom). Full-length blots are presented in Supplementary Fig. S8 .
could no longer tolerate growth in serum-free KSFM medium (Supplementary Table S2 ). Henceforth, all clones were grown in RPMI-1640 medium containing 10% FBS (R10). Injection of the large, soft agar clones into NOD/SCID mice found all 4 HBEC3 p53,KRAS,MYC clones were tumorigenic, whereas only 3 of 7 HBEC3
p53,KRAS clones formed tumors (Table 1) . Thus, even with 4 oncogenic changes and biologic selection there is dramatic clonal heterogeneity. This also showed that the tumorigenicity of the clones reflected the tumorigenicity of the parental population (when grown in R10) where approximately 40% of mice injected with HBEC3 p53,KRAS grew tumors compared with 100% of mice injected with HBEC3 p53,KRAS,MYC (Table 1) . Growth rate and tumor histology differed between tumorigenic clones. While subcutaneous tumors were largely undifferentiated (e.g., large cell and giant cell carcinomas), some xenograft tumors exhibited squamous and adenocarcinoma differentiation (Table 1 ). This differentiation was clone specific, as no clone differentiated into multiple histologies.
Oncogenic transformation of HBECs increases sensitivity to standard lung cancer chemotherapies
To determine if oncogenic transformation of HBECs altered their sensitivity to standard lung cancer chemotherapies, we tested 3 platinum-based doublets (paclitaxel-carboplatin, gemcitabine-cisplatin, and pemetrexed-cisplatin) currently in use for NSCLC treatment. Oncogenic manipulation of HBEC3 with sh-p53 and KRAS V12 resulted in a significant increase in sensitivity to gemcitabine-cisplatin and pemetrexed-cisplatin doublet therapy in vitro (approximately 6-and 10-fold, respectively) but not paclitaxelcarboplatin (Supplementary Table S3 and Supplementary  Fig. S5 ; one-way ANOVA; P < 0.001). Overall, the soft agar clones of HBEC3 p53,KRAS showed sensitivities comparable with the parental HBEC3 p53,KRAS cell line with clone 5 and 7 showing intermediate sensitivity. Thus, these tumorigenically progressed HBECs could provide a cell context appropriate, isogenic model system for identifying genetic differences regulating sensitivity and resistance to platinum doublet chemotherapy used in the treatment of NSCLCs.
mRNA profiles of tumorigenic versus nontumorigenic HBEC3
p53,KRAS soft agar clones predict prognosis and histology in clinical lung tumor specimens
The identification of tumorigenic and nontumorigenic clones of HBEC3 p53,KRAS that share the same genetic manipulations (sh-p53 and KRAS
V12
) and biologic selection (large, soft agar colonies) presents a unique cell model to characterize spontaneous transformation events that progress HBECs to full malignancy. Biochemical assays suggest the expression level of KRAS V12 is a major contributor toward full transformation (Figs. 1C and D and 5C ), whereas other tumorigenic events such as dysregulation of cell cycle did not differ between clones (Supplementary Fig. S6 ; summarized in Supplementary Table S2 ). To analyze molecular differences between tumorigenic versus nontumorigenic clones, the clones were profiled with whole-genome mRNA expression microarrays. The mRNA expression profile of each clone remained stable in culture as shown by comparing mRNAs collected at a 3-week interval in unsupervised clustering (Fig. 5D ). Tumorigenic and nontumorigenic clones separated into 2 distinct clusters suggesting the clones exhibit a strong expression profile associated with their tumorigenic phenotype, and supervised analysis comparing tumorigenic with nontumorigenic clones found 171 unique genes (203 probes) that were differentially expressed [Significance Analysis of Microarrays (SAM), False Discovery Rate (FDR) ¼ 5%; Supplementary Table S4; Fig. 5E ].
We tested the ability of the expression patterns of the 171 genes to predict overall survival and disease-free survival in 2 independent lung tumor cohorts; the SPORE dataset of resected early-stage NSCLCs (adeno-and squamous carcinomas; n ¼ 209) and a second dataset of primary lung adenocarcinoma samples (n ¼ 442; NCI Director's Challenge Consortium dataset). Prediction models were built using supervised principal component analysis and datasets were interchanged as training and testing datasets to test for robustness. Irrespective of dataset, the soft agar clone tumorigenic versus nontumorigenic signature was able to identify patients with significantly worse overall (Fig. 5F ) and recurrence-free ( Supplementary Fig. S7 ) survival. The successful application of a gene signature derived from an isogenic in vitro model of HBEC transformation in predicting outcome in clinical lung tumor samples indicates the power of such a system and provides a preclinical model for testing the functional importance of the genes in the signature.
Discussion
In this study, we sought to characterize the stepwise progression of lung cancer pathogenesis by introducing defined genetic manipulations commonly found in lung cancer into an in vitro HBEC model system (Fig. 6 ). We found the expression level of mutant KRAS is a critical transformative factor in HBECs, however, inactivation of p53 signaling is required to evade the tumor-suppressive barrier of RAS-induced senescence. We also show that EMT is an important oncogenic step, where c-MYC or growth in serum-containing medium both spontaneously induced an EMT and led to increased tumorigenicity. In HBECs derived from multiple individuals, we show 5 genetic changes (hTERT and Cdk4 to immortalize the cells, followed by p53 knockdown, mutant KRAS V12 , and c-MYC overexpression) together with serum-induced EMT are able to transform cells to a fully malignant state. Tumor xenografts of transformed HBECs were typical of lung cancer but varied in histology, suggesting histologically distinct lung cancers from the central bronchus may originate from a multipotent stem-like cell. Interestingly, clonal analysis of shp53þKRAS V12 -transformed HBECs found the isogenic cells exhibited distinct phenotypes in terms of in vivo tumorigenicity, xenograft histology, and drug response. The mRNA profile that distinguished tumorigenic from nontumorigenic clones was also able to identify a subset of primary lung tumor patients with significantly poorer survival. Together, this shows the use of the HBEC system as a preclinical model of lung cancer to understand transformation events.
Mutant KRAS lung cancers exhibit marked differences in the expression level of KRAS. We found the expression level of oncogenic KRAS V12 was an important factor in tumorigenic transformation of HBECs, suggesting it exerts its oncogenic effect in a dose-dependent manner, similar to HRAS V12 in a human mammary epithelial cell (HMEC) transformation model (18) . While higher levels of oncogenic KRAS enhanced HBEC transformation, it also triggered oncogene-induced senescence. Oncogene-induced senescence serves as an important tumor-suppressive barrier in response to persistent oncogenic insult by engaging proliferative arrest through p53 or p16/Rb (35) . We found that immortalized HBECs, where the p16/Rb pathway is bypassed as a result of overexpression of CDK4, could largely evade KRAS V12 -induced senescence with knockdown of p53. Loss of p53 function, therefore, is a key step in the malignant transformation of HBECs by allowing the cells to tolerate high levels of oncogenic KRAS, a driver of malignant transformation. Transformation studies in HMECs, which undergo spontaneous methylation-mediated p16 silencing, also report that high levels, but not low levels, of oncogenic RAS engage in senescence machinery (36, 37) . However, in HMECs, HRAS-induced senescence is mediated through TGF-b signaling in a p53-independent manner. Thus, the mechanism of RAS-induced senescence differs between in vitro epithelial cell models, most likely a consequence of immortalization methods or the cell of origin.
Our data show microenvironmental signals such as those provided by growth media can strongly influence the transformation of HBECs. Switching immortalized, but nontransformed HBECs from defined, serum-free culture medium to serum-containing medium induced inhibition of cell growth with induction of central airway differentiation markers. When immortalized HBEC with additional oncogenic manipulations are switched to serum-containing medium, however, the cells are able to bypass serum-induced differentiation and instead become mesenchymal and more tumorigenic, with a greater frequency of undifferentiated tumors.
Overexpression of c-MYC in HBEC3
p53,KRAS also induced an EMT and increased tumorigenicity. c-MYC has been shown to induce EMT in TERT-immortalized HMECs (38) . In our study, c-MYC induced EMT only in the presence of p53 and KRAS V12 alterations and not with c-MYC overexpression alone (data not shown). While c-MYC overexpression or growth in serum-containing media both caused HBEC3 p53,KRAS to undergo EMT and increase tumorigenicity, the presence of both manipulations had a synergistic effect resulting in full malignant transformation in HBECs from 2 individuals. This suggests their tumor-promoting effects signal through mutually exclusive pathways.
In the present study, we found interindividual differences in HBEC transformation suggesting HBECs derived from different donors can vary in their susceptibility to specific oncogene-induced malignant transformation. In terms of in vitro anchorage-independent transformation, neither cell line showed anchorage-independent growth following immortalization (CDK4 and hTERT), yet the combination of 5 genes (Cdk4, hTERT, sh-p53, KRAS V12 , and cMYC) resulted in a colony-forming efficiency of approximately 60% in HBEC3 compared with less than 15% in HBEC17. These differences could potentially stem from multiple factors including germline polymorphisms [such as singlenucleotide polymorphisms (SNP)], somatically acquired mutations derived from either the patient (such as age or environmental exposures) or laboratory practices (such as time in culture), or epigenetic mechanisms all of which may predispose the cells to oncogenic transformation. The patients from whom HBEC3 and HBEC17 were established, differ in respect to known risk factors for lung cancer such as age and smoking history, and it is likely they also differ in respect to unknown germline and/or somatic alterations. Thus, a comprehensive survey of genomic alterations present in HBECs before genetic manipulation (such as by whole-genome sequencing) would provide better indication of the level of existing premalignant susceptibilities, but these experiments are beyond the scope of the current study.
The lung can be divided into central and peripheral compartments (39) . SCCs usually arise from the central compartment, whereas adenocarcinomas may arise from either compartment, illustrating the importance of studying oncogenic transformation in both central and peripheral lung epithelial cell models. Many HBEC-derived tumors in our study were p63-positive with squamous differentiation, which likely reflects a stem/basal cell origin. A fewer number of tumors showed distinct dual squamous and adenocarcinoma differentiation or adenocarcinoma differentiation alone. A study using SV40-immortalized tracheobronchial and small airway epithelial cells found both cell types could be fully transformed with oncogenic RAS (8) . Another study using nonviral oncoproteins immortalized HSAECs with CDK4, hTERT, and a dominant-negative form of p53 (p53 CT ) and transformed the cells using low levels of KRAS V12 plus c-MYC, PIK3CA H1047R , cyclin D1, or LKB1 D194A (15) . In HBECs, we have shown p53 mutation is not required for immortalization (6) , and moreover, it increases oncogenic transformation (6, 12) . This disparity may signify intrinsic differences between centrally and peripherally derived immortalized epithelial cell models. Taken together, however, our study of defined oncogenic transformation of HBECs [both in the present study and previously (12) ] and the study in HSAECs by Sasai and colleagues (15) largely correspond with respect oncogenic transformation of bronchial epithelial cells. We previously showed transformation of HBECs with low levels of KRAS V12 (with CDK4, hTERT, and p53 knockdown) resulted in a modest increase in anchorage-independent growth but no tumor formation in vivo (12). Sasai and colleagues reported that transformation of HSAECs with low levels of KRAS V12 (with CDK4, hTERT, and p53 CT ) failed to yield anchorage-independent or in vivo growth. The authors were able to fully transform HSAECs using low levels of KRAS V12 only with additional genetic alterations. In the present study, we used a different approach by increasing the level of KRAS V12 expression to simulate the high amplification-associated expression often observed in lung cancer (40) . We found that higher levels of the oncogene resulted in increased in vitro and in vivo transformation compared with lower levels of KRAS V12 , which could be further increased with a fifth genetic alteration, such as cMYC overexpression. Thus, studies in HBECs and HSAECs show that increasing the number of oncogenic alterations will increase cellular transformation, whereas in the present study, we also show that increasing the level of certain oncogenic alterations can also increase transformation.
In conclusion, using the HBEC system as a progression model of lung cancer, we were able to study early transformative events in bronchial epithelial cells and the mechanisms used to overcome tumor-suppressive barriers. We show HBECs can be transformed to full malignancy by introducing defined genetic manipulations to produce histologically similar lung tumors in xenografts, indicating our in vitro HBEC model retains characteristics of the tissue of origin. Furthermore, we show HBECs can model preneoplastic changes and spontaneous transformation events such as oncogene-induced senescence and EMT and have clinically translatable applications as shown in isogenic clones exhibiting distinct drug response and tumorigenic phenotypes. Thus, genetically defined in vitro models such as HBECs will be an invaluable tool to assess the contribution of specific genes toward lung cancer pathogenesis, pertinent to recent whole-genome sequencing efforts, and to screen for novel therapeutic compounds directed at oncogenically acquired, tumor-specific vulnerabilities. 
